Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jul 28;21(1):377.
doi: 10.1186/s12888-021-03376-y.

The effects of bright light treatment on affective symptoms in people with dementia: a 24-week cluster randomized controlled trial

Affiliations
Randomized Controlled Trial

The effects of bright light treatment on affective symptoms in people with dementia: a 24-week cluster randomized controlled trial

Eirin Kolberg et al. BMC Psychiatry. .

Abstract

Background: The majority of people with dementia have behavioral and psychological symptoms of dementia (BPSD), including depression, anxiety and agitation. These may be elicited or aggravated by disrupted circadian rhythms. Bright light treatment (BLT) is a promising non-pharmacological approach to the management of BPSD, but previous research has yielded mixed results.

Methods: Eight nursing home dementia units (1 unit = 1 cluster) with 78 patients were invited to participate in a cluster randomized controlled trial from September 2017 to April 2018 investigating the effects of BLT on sleep and circadian rhythms (primary outcome) and BPSD (secondary outcome). Ceiling mounted LED-panels were installed in the intervention group (four units), providing light at 1000 lx and 6000 K (vertically at 1.2 m) between 10 a.m. and 3 p.m., with lower values in the mornings and evenings. Standard indoor light was used in the control group (four units). BPSD were assessed with The Cornell Scale for Depression in Dementia (CSDD) and the Neuropsychiatric Inventory Nursing Home Version (NPI-NH). Data collection took place at baseline and after 8, 16 and 24 weeks. Multilevel regression models with and without false discovery rate correction were used for the analysis, with baseline values and dementia stage entered as covariates.

Results: Sixty-nine patients were included in the study at baseline. Compared to the control group, the intervention group had a larger reduction on the composite scores of both the CSDD (95% CI = - 6.0 - - 0.3) and the NPI-NH (95% CI = - 2.2 - - 0.1), as well as on the NPI-NH Affect sub-syndrome, and the CSDD Mood related signs sub-scale at follow-up after 16 weeks. With FDR correction, the group difference was significant on the CSDD Mood related signs sub-scale (95% CI = - 2.7 - - 0.8) and the NPI-NH Affect sub-syndrome (95% CI = - 1.6 - - 0.2). No differences were found between conditions at weeks 8 or 24.

Conclusion: Compared to the control condition, affective symptoms were reduced after 16 weeks in the group receiving BLT, suggesting BLT may be beneficial for nursing home patients with dementia.

Trial registration: ClinicalTrials.gov Identifier: NCT03357328 . Retrospectively registered on November 29, 2017.

Keywords: Affective symptoms; Behavioral and psychological symptoms of dementia; Bright light therapy; Clinical trial; Dementia; Depression; Nursing homes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Phases of the light sequence in the intervention group. Illuminance (lux) and correlated color temperature (kelvin, K) at different times of the day in the intervention group, with gradual transition periods of 30 min separating each phase. Between 21:00 and 07:00 o’clock the lights could also be turned off by staff if this was preferred
Fig. 2
Fig. 2
Participant flow
Fig. 3
Fig. 3
Time spent in living room (daily average) between 10 a.m. and 3 p.m.* since the previous data collection. *Corresponding to the period of peak illumination (1000 lx and 6000 K) for the intervention group. Horizontal line = median, boxes = 25. – 75. percentiles, ends of whiskers = min / max. After exclusion of patients who spent < 30 min in the living room in this time period
Fig. 4
Fig. 4
Estimated marginal means for all outcome measures by week. Scale of y-axis adapted to each outcome separately. Scaled for visibility, not reflective of the full range of possible scores. CSDD = The Cornell Scale for Depression in Dementia, NPI-NH = The Neuropsychiatric Inventory Nursing Home Version
Fig. 5
Fig. 5
Standardized coefficients* and confidence intervals for the interaction between group (intervention vs. control) and time since baseline (week).*Predictors mean-centered, and dependent variable scaled. CSDD = The Cornell Scale for Depression in Dementia, NPI-NH = The Neuropsychiatric Inventory Nursing Home Version
Fig. 6
Fig. 6
Spearman correlations at baseline. Non-significant (p > 0.05) correlations crossed out. CSDD = The Cornell Scale for Depression in Dementia, NPI-NH = The Neuropsychiatric Inventory Nursing Home Version

References

    1. Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry. 2002;17(5):403–408. doi: 10.1002/gps.490. - DOI - PubMed
    1. Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350(mar02 7):h369. doi: 10.1136/bmj.h369. - DOI - PMC - PubMed
    1. Ruths S, Sorensen PH, Kirkevold O, Husebo BS, Kruger K, Halvorsen KH, et al. Trends in psychotropic drug prescribing in Norwegian nursing homes from 1997 to 2009: a comparison of six cohorts. Int J Geriatr Psychiatry. 2013;28(8):868–876. doi: 10.1002/gps.3902. - DOI - PubMed
    1. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–1943. doi: 10.1001/jama.294.15.1934. - DOI - PubMed
    1. Wang J, Yu JT, Wang HF, Meng XF, Wang C, Tan CC, Tan L. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015;86(1):101–109. doi: 10.1136/jnnp-2014-308112. - DOI - PubMed

Publication types

Associated data